New prostate cancer drug aims to block hormones without heart risks
Disease control
Not yet recruiting
This study tests a new drug called teverelix DP in 40 men with advanced prostate cancer. The goal is to safely lower testosterone to castrate levels using a specific dosing schedule. Participants receive injections on day 1 and then every 6 weeks. Results will help design a large…
Phase: PHASE2 • Sponsor: Antev Ltd. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC